Skip to content

Press Releases

Date Title
27/10/2021 Illumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease
20/10/2021 Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021
14/10/2021 Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL
13/10/2021 Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
30/09/2021 Illumina Expands Presence in Latin America
27/09/2021 Randomized trial demonstrates whole-genome sequencing leads to precision care for critically ill infants
15/09/2021 Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle
09/09/2021 Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050
07/09/2021 Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
30/08/2021 Illumina To Webcast Upcoming Investor Conference
18/08/2021 Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
05/08/2021 Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021
03/08/2021 Illumina Donates US $1 Million in Sequencing Capabilities for COVID-19 Genomic Surveillance in India
28/07/2021 Illumina to Webcast Upcoming Investor Conference
22/07/2021 Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase
13/07/2021 Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021
01/06/2021 Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis
27/05/2021 Illumina To Webcast Upcoming Investor Conference
17/05/2021 Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development
29/04/2021 Illumina To Webcast Upcoming Investor Conference
29/04/2021 Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition
28/04/2021 Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative
27/04/2021 Illumina Reports Financial Results for First Quarter of Fiscal Year 2021
22/04/2021 Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
20/04/2021 Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
05/04/2021 Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
30/03/2021 Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
18/03/2021 Illumina Announces Board Changes
11/03/2021 Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women
05/03/2021 Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia
11/02/2021 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020
10/02/2021 Illumina to Webcast Upcoming Investor Conference Presentations
08/02/2021 Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle
04/02/2021 Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium
31/01/2021 Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China
25/01/2021 Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021
20/01/2021 Illumina Wins Patent Infringement Suit against BGI in the UK
11/01/2021 New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale
11/01/2021 Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling
05/01/2021 Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure